216 related articles for article (PubMed ID: 29777112)
1. MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer.
Lin HM; Nikolic I; Yang J; Castillo L; Deng N; Chan CL; Yeung NK; Dodson E; Elsworth B; Spielman C; Lee BY; Boyer Z; Simpson KJ; Daly RJ; Horvath LG; Swarbrick A
Sci Rep; 2018 May; 8(1):7820. PubMed ID: 29777112
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
Armstrong CM; Liu C; Lou W; Lombard AP; Evans CP; Gao AC
Prostate; 2017 Jun; 77(9):1020-1028. PubMed ID: 28485104
[TBL] [Abstract][Full Text] [Related]
3. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
4. ERG induces taxane resistance in castration-resistant prostate cancer.
Galletti G; Matov A; Beltran H; Fontugne J; Miguel Mosquera J; Cheung C; MacDonald TY; Sung M; O'Toole S; Kench JG; Suk Chae S; Kimovski D; Tagawa ST; Nanus DM; Rubin MA; Horvath LG; Giannakakou P; Rickman DS
Nat Commun; 2014 Nov; 5():5548. PubMed ID: 25420520
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of anticancer activity of docetaxel by combination with Fuzheng Yiliu decoction in a mouse model of castration-resistant prostate cancer.
Fu W; Hong Z; You X; Din J; Chen B; Zhao B; Yuan G; Li Q
Biomed Pharmacother; 2019 Oct; 118():109374. PubMed ID: 31545228
[TBL] [Abstract][Full Text] [Related]
6. Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel.
Yang Z; Chen JS; Wen JK; Gao HT; Zheng B; Qu CB; Liu KL; Zhang ML; Gu JF; Li JD; Zhang YP; Li W; Wang XL; Zhang Y
J Exp Clin Cancer Res; 2017 Dec; 36(1):178. PubMed ID: 29216925
[TBL] [Abstract][Full Text] [Related]
7. Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner.
Wu F; Lin Y; Cui P; Li H; Zhang L; Sun Z; Huang S; Li S; Huang S; Zhao Q; Liu Q
Cancer Chemother Pharmacol; 2018 Jun; 81(6):999-1006. PubMed ID: 29605876
[TBL] [Abstract][Full Text] [Related]
8. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.
de Leeuw R; Berman-Booty LD; Schiewer MJ; Ciment SJ; Den RB; Dicker AP; Kelly WK; Trabulsi EJ; Lallas CD; Gomella LG; Knudsen KE
Clin Cancer Res; 2015 Feb; 21(4):795-807. PubMed ID: 25691773
[TBL] [Abstract][Full Text] [Related]
9. Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer.
Lee BY; Hochgräfe F; Lin HM; Castillo L; Wu J; Raftery MJ; Martin Shreeve S; Horvath LG; Daly RJ
Mol Cancer Ther; 2014 Jan; 13(1):190-201. PubMed ID: 24194567
[TBL] [Abstract][Full Text] [Related]
10. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
[TBL] [Abstract][Full Text] [Related]
11. Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells.
Watanabe H; Kawakami A; Sato R; Watanabe K; Matsushita Y; Miyake H
Anticancer Res; 2021 Aug; 41(8):3753-3758. PubMed ID: 34281834
[TBL] [Abstract][Full Text] [Related]
12. DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
Chao OS; Goodman OB
Prostate; 2021 Oct; 81(14):1032-1048. PubMed ID: 34297853
[TBL] [Abstract][Full Text] [Related]
13. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
Kato T; Mizutani K; Kameyama K; Kawakami K; Fujita Y; Nakane K; Kanimoto Y; Ehara H; Ito H; Seishima M; Deguchi T; Ito M
Urol Oncol; 2015 Sep; 33(9):385.e15-20. PubMed ID: 26027763
[TBL] [Abstract][Full Text] [Related]
14. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel-mediated autophagy promotes chemoresistance in castration-resistant prostate cancer cells by inhibiting STAT3.
Hu F; Zhao Y; Yu Y; Fang JM; Cui R; Liu ZQ; Guo XL; Xu Q
Cancer Lett; 2018 Mar; 416():24-30. PubMed ID: 29246644
[TBL] [Abstract][Full Text] [Related]
16. Identification of docetaxel resistance genes in castration-resistant prostate cancer.
Marín-Aguilera M; Codony-Servat J; Kalko SG; Fernández PL; Bermudo R; Buxo E; Ribal MJ; Gascón P; Mellado B
Mol Cancer Ther; 2012 Feb; 11(2):329-39. PubMed ID: 22027694
[TBL] [Abstract][Full Text] [Related]
17. LncRNA
Pucci P; Venalainen E; Alborelli I; Quagliata L; Hawkes C; Mather R; Romero I; Rigas SH; Wang Y; Crea F
Epigenomics; 2020 Jul; 12(13):1123-1138. PubMed ID: 32618200
[No Abstract] [Full Text] [Related]
18. Targeting the stress oncoprotein LEDGF/p75 to sensitize chemoresistant prostate cancer cells to taxanes.
Ríos-Colón L; Cajigas-Du Ross CK; Basu A; Elix C; Alicea-Polanco I; Sanchez TW; Radhakrishnan V; Chen CS; Casiano CA
Oncotarget; 2017 Apr; 8(15):24915-24931. PubMed ID: 28212536
[TBL] [Abstract][Full Text] [Related]
19. Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer.
Goto Y; Kurozumi A; Arai T; Nohata N; Kojima S; Okato A; Kato M; Yamazaki K; Ishida Y; Naya Y; Ichikawa T; Seki N
Br J Cancer; 2017 Jul; 117(3):409-420. PubMed ID: 28641312
[TBL] [Abstract][Full Text] [Related]
20. Exploiting epigenetic targets to overcome taxane resistance in prostate cancer.
Cevatemre B; Bulut I; Dedeoglu B; Isiklar A; Syed H; Bayram OY; Bagci-Onder T; Acilan C
Cell Death Dis; 2024 Feb; 15(2):132. PubMed ID: 38346967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
